Rep. Julia Letlow Sells Off Shares of AbbVie Inc. (NYSE:ABBV)

Representative Julia Letlow (R-Louisiana) recently sold shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on January 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in AbbVie stock on December 8th. The trade occurred in the Representative’s “MERRILL LYNCH INVESTMENT ACCOUNT #025” account.

Representative Julia Letlow also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 12/16/2025.
• Sold $1,001 – $15,000 in shares of Pinterest (NYSE:PINS) on 12/16/2025.
• Purchased $1,001 – $15,000 in shares of United Rentals (NYSE:URI) on 12/16/2025.
• Sold $1,001 – $15,000 in shares of Mettler-Toledo International (NYSE:MTD) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Icon Energy (NASDAQ:ICON) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Devon Energy (NYSE:DVN) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of AstraZeneca (NASDAQ:AZN) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Waters (NYSE:WAT) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of Warner Bros. Discovery (NASDAQ:WBD) on 12/8/2025.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $216.66 on Friday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The company has a market cap of $382.91 billion, a price-to-earnings ratio of 164.13, a PEG ratio of 0.91 and a beta of 0.36. The business’s 50 day moving average price is $226.89 and its 200-day moving average price is $216.08.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business’s revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is currently 496.97%.

Institutional Investors Weigh In On AbbVie

Several institutional investors have recently added to or reduced their stakes in ABBV. Vanguard Group Inc. lifted its stake in shares of AbbVie by 0.3% during the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after buying an additional 448,554 shares during the period. Geode Capital Management LLC grew its stake in AbbVie by 2.4% during the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock valued at $7,240,169,000 after purchasing an additional 924,761 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in AbbVie by 6.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock valued at $4,970,848,000 after purchasing an additional 1,517,222 shares during the last quarter. Norges Bank acquired a new position in shares of AbbVie in the second quarter valued at about $4,288,200,000. Finally, Legal & General Group Plc lifted its holdings in shares of AbbVie by 4.3% during the third quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock worth $2,779,426,000 after purchasing an additional 493,420 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on ABBV. Morgan Stanley boosted their price target on AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a report on Friday, December 12th. JPMorgan Chase & Co. increased their price target on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Evercore ISI lifted their price objective on AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a report on Monday, September 22nd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a research note on Thursday. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and raised their target price for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $247.84.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research raised AbbVie EPS estimates across multiple quarters and lifted FY2026 and FY2027 forecasts (small but consistent upward revisions), indicating analysts see stronger earnings ahead. (Zacks updates)
• Positive Sentiment: Pipeline and clinical progress: AbbVie reported completion of early human/Phase 1 work on ABBV‑CLS‑616 and on GUB014295 (obesity), which derisks parts of the pipeline and supports future growth potential. ABBV‑CLS‑616 phase 1 update GUB014295 trial completion
• Positive Sentiment: Business development and strategy: partnerships (e.g., RemeGen bispecific antibody) and management commentary at JPM underscore management’s push into oncology and obesity as key growth engines. RemeGen partnership Obesity market buildout
• Positive Sentiment: Large call-option buying (≈478k calls in one session) signals aggressive bullish bets from traders; this can amplify upside moves but also raise volatility and gamma risk for holders.
• Neutral Sentiment: Management reiterated a long-term growth story at JPM and features in industry write-ups highlight AbbVie’s pivoted pipeline strategy — useful context for long-term investors but not immediately market-moving. JPM presentation transcript
• Negative Sentiment: Shares have pulled back today (intraday/close weakness vs. broader market). Short-term pressure appears driven by profit-taking and the stock’s rich valuation (reported P/E ~164), which makes investors sensitive to any near-term miss or rotation away from growth names. Zacks: stock dips while market gains

About Representative Letlow

Julia Letlow (Republican Party) is a member of the U.S. House, representing Louisiana’s 5th Congressional District. She assumed office on April 14, 2021. Her current term ends on January 3, 2027.

Letlow (Republican Party) is running for re-election to the U.S. House to represent Louisiana’s 5th Congressional District. She declared candidacy for the primary scheduled on November 3, 2026.

Julia Letlow earned a doctorate. Letlow’s career experience includes working as a senior administrator with the University of Louisiana at Monroe.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.